Embed Size (px)
Citation preview
17 maart 2010
by Wim Smit
04/15/20231
In Vitro Diagnostiek “Bloedserieus”
04/15/20232
04/15/20233
About us!
Mission
• Future Diagnostics strives to become the best developer of high-quality and innovative diagnostic tests, today, and in the future seen in the eyes of our customers and our employees.
Vision
• Future Diagnostics strives to become the market leader in test development for third parties.
• We want to become the independent partner of the top 25 IVD companies for their test development.
• We would like to achieve this position by translating new technologies and novel ‘Intellectual Properties’ to the development of innovative tests with the shortest possible development time at the lowest possible costs.
Facts• Activities started May 01st, 1997
• Privately owned company, MBO completed Oct 5th, 2007
• 6 employees in1997 / current number of employees is 60
• Current number of projects is 34 / 40 available slots
• 19 Scientists with University degree
• 2 facilities: Nieuweweg and Edisonstraat
• Received ISO-9001/EN46001 certification Oct 97
• Received ISO 9001/2000 and ISO 13485 Oct 2003
• In compliance with the In Vitro Diagnostics Directive(IVDD) and the FDA’s Quality System Regulation (QSR) for medical devices
04/15/20236
Our Facilities
04/15/20237
Cardiovascular Endocrine Infectious disease
AngiotensinANPBNPCatecholaminesCK-MBD-DimerFactor VIIIFibrin-monomerFibrinogenGalectin-3HS-CRPMyoglobinNT Pro-BNPProtein-CPro-reninReninsPLA2 activitycTroponin-IVasopressinvWF
ACTHAnti-TgAnti-TPOC-peptideCorticosteronCortisolCortisonFecal Occult BloodFree T3GastrinGHBPhGHHeparin Induced ThrombocyopeniaIL-2 receptorIL-6InsulinMelatoninNewborn screeningThyroglobulin
Anti-HBcAnti-HBsChlamydiaCMV IgG+IgMEBVGonoreaHBcTHBsAg confirmativeHCVHIV AbHIV Ab+AgHIV-1,2,”O”LymeRubella IgG+IgMSyphilisToxoplasmose IgG+IgMTuberculosis
04/15/20238
Assays for > different analytes!
Assays for > different analytes!
04/15/20239
Bone Fertility Cancer
Bioactive PTHCalcitoninCip and CapDPDIntact-PTHPTHPTHrp1,25-OH Vitamin D25-OH Vitamin DVitamin D binding protein
AldosteroneAndrosteendione11-Desoxy-cortisolDHEADHEASDHTEstradiolFree testosteronehCGLH17-OH ProgesteroneSHBGTestosteroneu-E3
b-2MEGFEGF receptorE2 receptorIGF-1IGFBP3P53Progesterone receptorPSA
04/15/2023
IntraOperative AutoimmuneSTAT-ACTHSTAT-C-peptideSTAT-InsulinSTAT-PTH
Anti-Cardiolipin IgG+ IgMAnti-GADAnti-IA2Anti-InsulinAnti-SMSMultiplex auto antibodies
10
Anemia Others
EPOFerritinFolateVitamin B12
AtrazinecGMPCGRPCow milk ProgesteroneDESFPAGFAP
HbA1cRhodopsinSalbutamolS100tPA-PAI-1uPA-PAI-1TyrosineKinase
Assays for > different analytes!
04/15/202311
Customers
Confidential
04/15/202313
Experience on automated platforms
04/15/202314
• Development of diagnostic tests on different automated platforms.
• Prototyping of POC tests for diagnoses in the areas of surgery, transplantation, stroke, minor and severe head injury.
• Research on new, innovative and sensitive technologies in the area of “near to patient testing”.
Area’s of major interest
04/15/202315
Trends, Opportunities & Threats in the Healthcare!
Source: TriMark Publications
• Less than 5% of the $3 trillion spent each year on the health care worldwide is for clinical laboratory services.
• Considering that nearly 70% of health care decisions are based on critical diagnostics information, biomedical testing represents a significant source of value in healthcare.
Trends in healthcare
Source: TriMark Publications
04/15/202317
04/15/202318
Demographic changes, increase in average age.
Reducing healthcare costs by increasing use IVD tests.
Technological development, new tests and markers
Point of Care testing outside the laboratory directly to the patient, ambulance, first aid or doctor.
Further automation of instruments and laboratories.
Trends in healthcare
Source: TriMark Publications
04/15/202319
Point Of Care???
20
The purpose of point of care testing is the provision of a test result at the most appropriate point in time; enabling a decision on action to be taken that will result in an improved health outcome, without incurring additional costs.
There is a need to develop point of care platforms that are able to perform a wide menu of complex in vitro diagnostic tests from minute samples, with the accuracy associated with laboratory systems.
POC opens the door for change for the In Vitro Diagnostics & Healthcare.
Source: TriMark Publications
21
POC opens the door for change for the In Vitro Diagnostics & Healthcare.
For blood testing, it offers the option of moving some complex immunoassays out of the lab, saving more lives by speeding up the tests needed to detect life-threatening conditions.
There is already a trend away from centralised treatment and testing to one which delivers care in a more patient-friendly way. We are convinced that improving point-of-care testing in acute settings in the hospital and at home is in the best interest of patients.
Source: TriMark Publications
04/15/202322
04/15/202324
04/15/202325
• Small sample volume (fingerpick drop of blood or saliva)
• Ease of use (potentially applicable for home testing, GP & specialist office)
• Multi-analyte (several analytes can be measured simultaneously)
• Lab-quality sensitivity
• Speed (measurement in 5-10 minutes depending on the application)
Magnotech handheld technology has the potential to deliver:
04/15/202326
1. Preloaded Magnetic nanoparticles in disposable cartridge.2. Automatically disperse into the sample as the cartridge fills
with saliva or blood.3. Magnetic nanoparticles quickly bind to target molecules in
the fluid sample. 4. An electromagnet field brings the magnetic nanoparticles
into contact with the active detection surface of the biosensor
5. A second magnetic field separates any unbound magnetic particles away from the active surface.
6. Measurement is done using an optical technique based on internal reflection.
The Philips’ Magnotech handheld:The underlying technology.
27
Philips
Future Diagnostics
04/15/202328
Thank you
Questions?
